U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H26FN3O4
Molecular Weight 415.4579
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLESINOXAN

SMILES

OC[C@H]1COC2=C(C=CC=C2O1)N3CCN(CCNC(=O)C4=CC=C(F)C=C4)CC3

InChI

InChIKey=NYSDRDDQELAVKP-SFHVURJKSA-N
InChI=1S/C22H26FN3O4/c23-17-6-4-16(5-7-17)22(28)24-8-9-25-10-12-26(13-11-25)19-2-1-3-20-21(19)29-15-18(14-27)30-20/h1-7,18,27H,8-15H2,(H,24,28)/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H26FN3O4
Molecular Weight 415.4579
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

FLESINOXAN, a phenylpiperazine derivative, is a selective agonist for 5-HT1A receptors. It is an antidepressant agent which clinical development was stopped.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.7 nM [Ki]
PubMed

PubMed

TitleDatePubMed
Rocuronium-induced neuromuscular block after long pretreatment of clonidine in rabbits.
2010-09
5-HT1A receptor blockade reverses GABA(A) receptor alpha3 subunit-mediated anxiolytic effects on stress-induced hyperthermia.
2010-08
Chronic thromboembolic pulmonary hypertension.
2010-04
Peripheral 5-HT1A and 5-HT7 serotonergic receptors modulate parasympathetic neurotransmission in long-term diabetic rats.
2010
Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy.
2010
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs.
2009-08-06
Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis.
2008-12
Activation of 5-HT1A autoreceptors in the dorsal raphe nucleus reduces the behavioral consequences of social defeat.
2008-10
Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models.
2008-09
Stress-induced hyperthermia and basal body temperature are mediated by different 5-HT(1A) receptor populations: a study in SERT knockout rats.
2008-08-20
The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
2008
Acute flesinoxan treatment produces a different effect on rat brain serotonin synthesis than chronic treatment: an alpha-methyl-l-tryptophan autoradiographic study.
2007-12
Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man.
2007-11
SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
2007-01
Delay aversion: effects of 7-OH-DPAT, 5-HT1A/1B-receptor stimulation and D-cycloserine.
2006-12
Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat.
2006-09
5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala.
2006-02-17
Contractile effects of 5-hydroxytryptamine and 5-carboxamidotryptamine in the equine jejunum.
2006-01
Early response and 8-week treatment outcome in GAD.
2006
5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior.
2005-12-01
Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling.
2005-12
The effect of a 5-HT1A receptor agonist on striatal dopamine release.
2005-08
Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6.
2005-04-30
Behavioral and physiological mouse models for anxiety: effects of flesinoxan in 129S6/SvEvTac and C57BL/6J mice.
2004-06-21
Effects of repeated testing in two inbred strains on flesinoxan dose-response curves in three mouse models for anxiety.
2004-06-21
Influence of 5-HT1 receptor agonists on feline stomach relaxation.
2004-05-25
Effects of the 5-HT1A receptor ligands flesinoxan and WAY 100635 given systemically or microinjected into the laterodorsal tegmental nucleus on REM sleep in the rat.
2004-05-05
Occupancy of agonist drugs at the 5-HT1A receptor.
2004-05
Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study.
2004-03
Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats.
2004-03
In vivo characterization of 5-HT1A receptor-mediated gastric relaxation in conscious dogs.
2003-11
Ca2+ responses in Chinese hamster ovary-K1 cells demonstrate an atypical pattern of ligand-induced 5-HT1A receptor activation.
2003-11
Differential effects of the 5-HT1A receptor agonist flesinoxan given locally or systemically on REM sleep in the rat.
2003-10-08
Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
2003-09
Modulation of 5-HT(1A) receptor-mediated Ca(2+) responses by co-expression with various recombinant G(alpha) proteins in CHO-K1 cells.
2003-08
Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys.
2003-07
Mutation in a protein kinase C phosphorylation site of the 5-HT1A receptor preferentially attenuates Ca2+ responses to partial as opposed to higher-efficacy 5-HT1A agonists.
2003-06
Modulation of passive avoidance in mice by the 5-HT1A receptor agonist flesinoxan: comparison with the benzodiazepine receptor agonist diazepam.
2003-04
Nad-299 antagonises 5-HT-stimulated and spiperone-inhibited [35S]GTPgammaS binding in cloned 5-HT1A receptors.
2002-12-31
Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers.
2002-10
Neuroendocrine evaluation of 5-HT1A function in male alcoholic patients.
2002-10
Psychopharmacology of anxiety disorders.
2002-09
Autonomic changes associated with enhanced anxiety in 5-HT(1A) receptor knockout mice.
2002-09
5-HT1A dysfunction in borderline personality disorder.
2002-07
Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan.
2002-06-07
The interaction between the locus coeruleus and dorsal raphe nucleus studied with dual-probe microdialysis.
2002-06-07
[Effect of (+/-)-pindolol on the central 5-HT1A receptor by the use of in vivo microdialysis and hippocampal slice preparations].
2002-06
[Participation of 5-HT1A-receptors in regulating various types of aggressive behavior].
2002-03-02
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
1998-08-21
Differential cardiovascular effects of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), flesinoxan, 5-methyl-urapidil and MDL 75,608A in conscious spontaneously hypertensive rats.
1993
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:49:37 GMT 2025
Edited
by admin
on Mon Mar 31 18:49:37 GMT 2025
Record UNII
3V574S89E1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLESINOXAN
INN   MI  
INN  
Official Name English
(+)-(S)-P-FLUORO-N-(2-(4-(2-(HYDROXYMETHYL)-1,4-BENZODIOXAN-5-YL)-1-PIPERAZINYL)ETHYL)BENZAMIDE
Preferred Name English
flesinoxan [INN]
Common Name English
FLESINOXAN [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
Code System Code Type Description
WIKIPEDIA
Flesinoxan
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
PUBCHEM
57347
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
CAS
98206-10-1
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
EVMPD
SUB07640MIG
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
ChEMBL
CHEMBL1742477
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
SMS_ID
100000080992
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
INN
5957
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
FDA UNII
3V574S89E1
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
MESH
C056895
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
MERCK INDEX
m1163
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C80760
Created by admin on Mon Mar 31 18:49:37 GMT 2025 , Edited by admin on Mon Mar 31 18:49:37 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY